Smith & Nephew SNATS (NYSE: SNN) — Perfil da empresa, notícias e dados financeiros
Smith & Nephew SNATS develops medical devices across orthopedics and wound management, focusing on enhancing patient care.
Smith & Nephew SNATS
Smith & Nephew SNATS is a portfolio medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates globally across three main business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its product offerings include hip and knee replacement implants, robotic-assisted surgical systems, trauma fixation devices, sports medicine soft tissue repair instruments, negative pressure wound therapy systems, and advanced wound care dressings. Headquartered in the United Kingdom, the business serves healthcare professionals, hospitals, ambulatory surgery centers, and clinics across major international markets in North America, Europe, Asia-Pacific, and Latin America.
Resumo
Operações
Produtos e/ou serviços de Smith & Nephew SNATS
- Orthopaedic Knee and Hip Implants: Reconstructive joint replacement systems including the LANDMARK and JOURNEY II total knee platforms, RI.HIP navigation software, and cementless porous joint implants designed for orthopaedic reconstruction in hospital operating rooms and ambulatory surgery centers.
- Sports Medicine Soft Tissue Repair: Minimally invasive surgical devices, tissue repair tools, and bioinductive implants including the REGENETEN implant and FAST-FIX FLEX meniscal repair system engineered to treat ligament, tendon, and joint injuries across shoulder, knee, and hip procedures.
- Advanced Wound Management Dressings: Multilayered therapeutic dressings including ALLEVYN foam adhesive products and bio-cellular skin substitutes formulated to treat complex chronic wounds, diabetic foot ulcers, pressure injuries, burns, and post-operative surgical sites across acute and community healthcare settings.
- Trauma and Extremities Fixation: Specialized trauma hardware, internal and external fixation devices, small fragment plating systems, and dedicated intramedullary nails engineered to stabilize complex bone fractures, correct anatomical deformities, and promote structural skeletal healing in emergency surgical care.
- Negative Pressure Wound Therapy Systems: Single-use and canister-assisted negative pressure therapy solutions including the PICO 14 and RENASYS systems engineered to manage wound exudate, close surgical incisions, prevent complications, and accelerate healing in post-operative and chronic care environments.
- Ear, Nose and Throat Surgical Devices: Specialized otolaryngology surgical tools utilizing low-temperature COBLATION bipolar radiofrequency technology, RAPID RHINO nasal packing, and automated Tula tympanostomy tube delivery devices engineered for turbinate reduction, tonsillectomy, sinus surgery, and outpatient ear procedures.
equipe executiva do Smith & Nephew SNATS
- Deepak S. NathCEO & Director
- Pierre PalassianInterim CFO, Senior VP of Finance & Group Controller
- Paul ConnollyPresident of Global Operations
- Emily HeavenHead of Investor Relations
- Helen BarracloughGroup General Counsel & Company Secretary
- Alison ParkesChief Compliance Officer & Compliance APAC
- Charles ReynoldsHead of Corporate Communication
- Ajay DhankharChief Corporate Development & Strategy Officer
- Elga LohlerChief Human Resources Officer
- Vasant PadmanabhanPresident Research & Development, ENT and Emerging Markets
Histórico de dividendos
Dividendos por ação pagos pela Smith & Nephew SNATS, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.7940 |
| FY2025 | — | — | — | $0.7620 |
| FY2024 | — | — | — | $0.7500 |
| FY2023 | — | — | — | $0.7500 |
| FY2022 | — | — | — | $0.7500 |
Principais indicadores financeiros
Resultados divulgados pela Smith & Nephew SNATS, em USD.
- Cap. de mercado
- 12,6 bi
- Receita (TTM)
- 6,3 bi
- P/L
- 20.5
- LPA (diluído, TTM)
- 1.5
- Dividend yield
- 2.6%
- Margem de lucro
- 10.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 6,2 bi | 794 mi | 625 mi | |
| 5,8 bi | 657 mi | 412 mi | |
| 5,5 bi | 425 mi | 263 mi | |
| 5,2 bi | 450 mi | 223 mi |